Edge Therapeutics Inc. (EDGE) announced Wednesday morning that it will discontinue its Phase 3 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage based on the recommendation of the independent Data Monitoring Committee.
from RTT - Before the Bell https://ift.tt/2pMfw6m
via IFTTT
No comments:
Post a Comment